| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0de4b9e83a5608cf8da267add64afdf5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-46 |
| filingDate |
1994-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1997-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8943b2bad8e2a6afbad4b9c13c860ad8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae4587e461dc5c3f73b992d02ddef9e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30aae5fcc7c11fc630c4e8acd116a011 |
| publicationDate |
1997-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5614494-A |
| titleOfInvention |
Peptides for heparin and low molecular weight heparin anticoagulation reversal |
| abstract |
Less toxic agents for reversal of heparin or low molecular weight heparin anticoagulation which are synthetic protamine-like polycationic peptides having a total cationic charge which is less than that of n-protamine. In preferred embodiments, arginine residues of n-protamine are replaced with lysine residues for ease of manufacture. Selective positively charged arginine residues have been replaced with an uncharged amino acid residue or its analog, such as glycine or glutamine, in order to reduce the total cationic charge on the polycationic peptide to the range of about [+14] to [+18], preferably [+16] to [+18]. In specific embodiments, there are sequences of 29 and 32 amino acid residues wherein 4 to 5 clusters of 2 to 4 positively charged amino acids are separated by 2 to 6 neutral amino acids. The C-terminus and the N-terminus can be modified to mitigate against in vivo degradation by carboxypeptidases and aminopeptidases. Another modification, specifically use of alpha -helix forming amino acids, such as glutamic acid, further promotes anticoagulation reversal. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8519189-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012308546-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10111902-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113943345-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5919761-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8637008-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110393803-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013049149-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9095666-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113943345-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10441606-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110393803-B |
| priorityDate |
1993-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |